A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Terminated · Phase 1 · NCT03484520
Conditions: Cancer - Acute Myeloid Leukemia
At a glance
- Research payments reported, 2025
- $3,900
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- AbbVie (with Merck Sharp & Dohme LLC)
- Tested
- Venetoclax (drug), Dinaciclib (drug)
- Dates
- Started 2018-07-23; completion 2022-12-01
- Results posted
- Not yet
An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML).
From ClinicalTrials.gov, last updated 2022-12-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3,900 in research payments for this study in 2025 (2 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Chicago $3,900
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.